Supernus Pharmaceuticals, Inc. (Supernus) is a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. Supernus is developing several product candidates in neurology and psychiatry to address opportunities in epilepsy and attention deficit hyperactivity disorder (ADHD). Supernus’s two epilepsy product candidates are SPN-538 and Epliga. Epliga is in Phase III clinical trials. Supernus ADHD product candidates include SPN-810 (molindone hydrochloride), a treatment for impulsive aggression in patients with ADHD, and SPN-812, a non-stimulant treatment for ADHD. Both of these programs are in Phase II. In addition to these four products candidates, Supernus has several additional product candidates in various stages of development, including SPN-809. Its wholly owned subsidiary includes TCD Royalty Sub LLC.
Rexahn Pharmaceuticals, Inc. (NYSE Amex: RNN), a clinical stage pharmaceutical company developing and commercializing potential best in class oncology and CNS therapeutics, today announced that it has submitted an investigational new drug application (IND) to the Food and Drug Administration for a first-in-human study of RX-5902 to treat advanced or metastatic solid tumors. RX-5902 is a first-in-class small molecule that inhibits the phosphorylated p68 RNA helicase, a protein that plays a key role in cancer growth, progression and metastasis. The phosphorylated form of p68 RNA helicase is only present in cancer cells and is absent in normal cells.
“RX-5902 is an exciting first-in-class p68 RNA helicase inhibitor that has considerable commercial potential,” said Rick Soni, President of Rexahn. “Pre-clinical studies have shown that RX-5902 exhibits very potent anti-tumor activity in various cancers including melanoma, renal, ovarian and pancreatic. Additional studies suggest that RX-5902 is effective in drug-resistant cancer cells and is synergistic when combined with current cancer drugs.”
About Rexahn Pharmaceuticals, Inc.
Ampio Pharmaceuticals ( NASDAQ: AMPE ) stock jumped more than 30% to $5.16 and touched an intraday high of $5.50. There was not specific announcements from the company regarding any developments. Up move might last if there might be an insider news or announcements, that might come later today or tomorrow. Traders should follow it closely for a momentum trade. Last development news from company was on June 11 2012, when company has announced a positive clinical trial data for its drug Optina used in Diabetic macular edema. Read belowAmpio Pharmaceuticals Inc announced that it's CRO has completed analysis of the primary end point in the Optina clinical trial for DME conducted at St Michael Diabetes Hospital in Toronto Canada. The primary end point for efficacy was central subfield retinal thickness as measured by Optical Coherence Tomography (OCT) and reported in microns. The study was double masked and included 32 patients with moderate to severe diabetic macular edema (range 316-707microns) that were treated orally with either placebo or one of three doses of Optina. Central retinal thickness and retinal volumes were measured at baseline and at four and 12 weeks of treatment. The results confirm a significant interaction between the patient's body mass index (BMI) and efficacy at the different doses of Optina. For higher BMI (BMI=35) patients, higher doses of Optina were more effective and for lower BMI (BMI=26) patients, lower doses were more effective. The improvement of efficacy by adjusting the dose to the BMI is in agreement with both in vitro data as well as with the known strongly lipophilic nature of Optina. At one of the low doses, regardless of BMI, there was a reduction of the subfield central retinal thickness of approximately 20% at four and at 12 weeks, which was statistically significant from placebo for the higher BMI group (p = 0.01).
Stock of the company Freeze tag Inc ( OTC: FRZT ) rallied as high as $0.08 and still holding more than 100 % of upside. There was not any announcements from the company and up move might look fishy. We advised not to trade the stock until the company announcements released.
Keryx Biopharmaceuticals ( NASDAQ: KERX ), stock moving higher without any news or announcement from the company. Stock has jumped more than 50 % in last 3 trading session. Active penny stock traders might follow the stock for possible developments from the company. Stock trading at $2.20.
Watch out for big move.Biodel Inc ( NASDAQ:BIOD ), stock jumped more than 20% after yesterday's sharp sell off in the stock. No announcements from the company regarding any development. Big players might preparing for upcoming news events as there might be a positive developments.
 |
| Biodel Inc |
NF Energy Savings Corp ( NASDAQ: NFEC ), stock jumped more than 30% and up about 20% to $2.41 without any specific news or announcements. Volumes are already ten times higher than average. Up move might not convincing and there is a higher risk to initiate buy positions at this levels.
 |
| NF Energy Savings Corp. |
Our Call : Cautious call, Might prefer to stay away before any news announcements.
Penny Stock Recon Technology Ltd ( NASDAQ: RCON ), stock jumped more than 60 % without any specific news. Volumes are picking up as more intraday traders participating i the trade. One might consider small trading opportunity for intraday gains.
Our Call: Small trade positions might be initiated at current levels.
Catalyst Pharmaceuticals Partners Inc ( NASDAQ: CPRX ), a small biotech company sneakily moving up since last few trading sessions. Stock has logged more than 36 % upside in last 3 trading sessions. Traders might keep an eye on the stock as you might see a huge breakout in the stock. As of now, there is no announcements from the company regarding any development.
Our Call: Keep an eye on the stock and wait for any positive development announced from the company.
Smart-Tek Solutions Inc ( PINK:STTN ), penny stock moving up without specific development news. Stock is trading up more than 42 % and volumes are also abnormal.
Our Call: Cautious call for trade as stock might not see much upside
Our Call: Cautious call for trade as stock might not see much upside
High Plains Gas Inc ( OTC: HPGS ), Stock jumped more than 62 % to $ 1.20 in the morning trade. There was o specific news or announcements relevant to company's developments. Volumes are much stronger and traders might take buy positions as stock might see more upside at this level.
Our Call: Buy positions may be initiated only for intraday trade.
Last news from the company was it has amended a pact with J.M huber corporation on June 1st 2011.
High Plains Gas Inc announced the amendment of the Purchase and Sale Agreement between High Plains and J.M. Huber Corporation. The transaction involves certain coalbed methane assets in Wyoming and Montana and has been extended. The amendment expires June 30, 2011, but has provisions which allow the parties to either close or cancel the amendment prior to that date. Details of the transaction were first announced on February 27, 2011. This amendment grants High Plains Gas, Inc. additional time to close the purchase of Huber's Powder River Basin coalbed methane assets as amended. Huber has the right to pursue sales to third parties and may terminate the agreement upon written notice and pursue actions that it deems appropriate. High Plains may notice Huber at anytime of its intentions to close the transaction prior to any termination notice and the transaction may proceed to close. Huber continues to hold non-refundable deposits in the amount of $2 million and 2 million shares of HPGS common stock which may be applied towards the closing price.
Our Call: Buy positions may be initiated only for intraday trade.
Last news from the company was it has amended a pact with J.M huber corporation on June 1st 2011.
 |
| High Plains Gas Inc |
Brinx Resources Ltd ( PINK: BNXR ) stock jumped 34% without any specific news or announcements. Volumes are more than 2.5 millions shares. Stock move might be consider a technical breakout and high risk traders might consider trading the stock for intraday gains. Open positions might not carry forward.
 |
| Brinx Resources Ltd |
Our Call: High risk trade, very cautious on buying for intraday gains.
As per our last alert on the stock Westinghouse Solar Inc ( NASDAQ: WEST ) on June 1st to trade the stock for intraday gains ( Read Here ). Stock has logged 99% upside during the trading session. Today stock exploded to another 31% to close to $ 2.50. What to do now?
Our Call: Small buy positions for intraday trade purpose may be initiated but cautious call as stock might see profit booking later today or tomorrow. Don't consider as investment positions.
Penny Stock exploded : Broadcast Mrktg New ( PINK : BDCM ) up more than 420% without any specific news or announcements. Volumes are much above than average but its not significant enough as stock price is just 37 cents.
There is not enough response form penny stock traders as volumes haven't reached a million share trade. Cautious call for trade.
Our Call: Stay away, Don't initiate any positions.
There is not enough response form penny stock traders as volumes haven't reached a million share trade. Cautious call for trade.
Our Call: Stay away, Don't initiate any positions.
Catalyst Pharmaceuticals inc ( NASDAQ: CPRX ),stock moved up more than 19 % without specific news. Volumes are much higher than average. Stock touched a new 52 week high of $ 1.57, it might be a break out based on some developing news. Good play for Intraday trade.
Our Call : Buy positions might be initiated and might stay long for couple of days, or more depending on risk appetite.
Company analysis and report:
Company might be a takeover target and also offers a value buy as stock has much upside left below is some analysts price targets on the stock First Albany had a $10 price target, while Stifel Nicolaus and Rodman and Renshaw both had $9 price targets with buy ratings. The buy ratings and $9 to $10 price targets were just before the financial crisis, and it seems like everyone has forgotten about this little biotech that clearly still has potential and has made significant progress over the past four years. One analyst still has a $9 price target,
CPRX has a very low burn rate compared to most biotechs; management has been conservative and made substantial purchases of this stock. The 52-week high is $1.54 and with volume picking up and the shares only about 30 cents away from that level, it looks like these shares could be ready to make new highs soon. The chart for this stock looks good as well, with the 50-day moving above the 200-day moving average, the chart shows a new golden cross formation, which often indicates the start of a new upward trend.
Catalyst has some big players invested in its stock. Federated Investors owns nearly 12% of this company and FMR, LLC (Fidelity) owns about 6%. Late last year, Catalyst began a $10 million clinical trial, the majority of which (about $7.2 million) is being paid by the government. The trial is for CPP-109, "Vigabatrin," to treat cocaine addiction. The company also has CP-115, which it says "has the potential to address a broad range of diseases affecting the central nervous system beyond addiction, such as adult epilepsy and infantile spasms." What intrigues me most about this is the following portion:
In 2010, Reckitt Benckiser's Suboxone(R) and Subutex(R) became the first addiction drugs to achieve "blockbuster" status with combined U.S. sales of over $1 billion. Recognition of this milestone, along with the looming "patent cliff" faced by the world's largest pharmaceutical companies, has increased the number of companies interested in discussions about partnering opportunities for CPP-109 and CPP-115. While no definitive partnering agreements have been entered into to date, Catalyst's goal is to make significant progress on this front before the end of 2011.
An agreement to partner with a major pharmaceutical company would potentially send this stock soaring from current levels. CPP-109 has been granted fast track status by the FDA for the treatment of cocaine addiction, which indicates that the FDA has recognized that CPP-109 is intended for the treatment of a serious or life-threatening condition for which there is no effective treatment and which demonstrates the potential to address unmet medical needs. With a market cap of only about $24 million and the potential to bring a blockbuster drug to market, it would not be surprising to see a major company takeover CPRX or announce a major partnership agreement, which is one of the company goals for 2011.
Evader Inc ( PINK: EVDR ), penny stock jumped more than 100 % with out specific news or announcements. Volumes are much stronger than daily average, Up move look convincing and stock might see further upside.
Our Call : Buy positions for Intraday trade, not to hold positions for even tomorrow.
Last news from the company was submission of a tender in the state of Tamil Nadu worth 110 million USD through its subsidiary Ascc Constructions.
Our Call : Buy positions for Intraday trade, not to hold positions for even tomorrow.
Last news from the company was submission of a tender in the state of Tamil Nadu worth 110 million USD through its subsidiary Ascc Constructions.
EntreMed Inc ( NASDAQ: ENMD ), stock of the company jumped more than 42 %, without specific news or announcements from the company.Traders might keep an eye on the stock as some news development might be announced.
Our Call: Cautious trade, Wait for news before buying stock
Our Call: Cautious trade, Wait for news before buying stock
Corinthian Colleges Inc ( NASDAQ: COCO ), stock of the company jumped more than 38% in the morning trade as company announced a partnership with custom motorcycle shop. Volumes and options activity are trending a bullish breakout as per below. There was a spike in yesterday's trading session.
Our Call: Buy positions for trade and investment purpose.
Below is the news:
"Orange County Choppers" is a hot trend Thursday after WyoTech, a division of Corinthian Colleges(COCO),announced a partnership with the custom motorcycle shop.
Under the partnership, WyoTech students will help construct a custom-built motorcycle with the guidance of OCC founder Paul Teutul Sr., and students also will intern at the facility in upstate New York. The bike will be revealed this fall on an episode of "American Chopper" on the Discovery Channel.
Options Activity:
 |
| Corinrhian Colleges Inc |
The COCO June 4 calls were the second-busiest contract, trading more than 5,000 times for $0.15 to $0.30. CECO's June 23s and June 24s followed with volume of 4,301 and 3,640, respectively.
Including ITT Educational Services, overall option volume in the group was 8 times greater than average. Calls accounted for a bullish 78 percent of the activity in the four names, with purchases dominating the order flow.
The stocks have been getting killed since April 2010 after government officials expressed an intention to tighten student-loan standards. The 12-month declines range from 17 percent by CECO and 69 percent by COCO, but the stocks have shown signs of stabilizing in about the last month.
Although the rules may seem draconian, the market has already priced in considerable negative news. Given that these companies have considerable short interest, little debt, and trade at deeply discounted multiples, clarity on the regulatory backdrop could draw more investors back to the sector.
